Rep. Dan Newhouse Sells Off Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Representative Dan Newhouse (R-Washington) recently sold shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on May 16th, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on April 11th. The trade occurred in the Representative's "EDWARD JONES IRA" account.

Representative Dan Newhouse also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of PayPal NASDAQ: PYPL on 4/11/2025.
• Sold $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Moody's NYSE: MCO on 4/11/2025.
• Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Dollar General NYSE: DG on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 4/11/2025.
• Sold $1,001 - $15,000 in shares of BlackRock NYSE: BLK on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 4/11/2025.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded up $9.59 on Tuesday, hitting $403.25. The company's stock had a trading volume of 2,705,443 shares, compared to its average volume of 1,872,756. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock's 50 day moving average is $437.74 and its 200-day moving average is $502.70. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The company has a market capitalization of $152.22 billion, a PE ratio of 24.40, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the prior year, the company posted $5.11 earnings per share. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analysts Set New Price Targets

Several equities analysts recently commented on TMO shares. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Raymond James reiterated an "outperform" rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $607.43.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Stonegate Investment Group LLC raised its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock valued at $3,531,000 after buying an additional 18 shares during the last quarter. Semus Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.0% in the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after buying an additional 18 shares during the last quarter. Eagle Rock Investment Company LLC raised its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock valued at $3,882,000 after buying an additional 19 shares during the last quarter. KRS Capital Management LLC raised its holdings in Thermo Fisher Scientific by 1.5% during the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock worth $685,000 after purchasing an additional 20 shares during the last quarter. Finally, Evernest Financial Advisors LLC raised its holdings in Thermo Fisher Scientific by 4.0% during the 4th quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock worth $271,000 after purchasing an additional 20 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is currently owned by insiders.

About Representative Newhouse

Dan Newhouse (Republican Party) is a member of the U.S. House, representing Washington's 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Newhouse (Republican Party) ran for re-election to the U.S. House to represent Washington's 4th Congressional District. He won in the general election on November 5, 2024. Click here to see Newhouse's key votes in Congress. Newhouse served as a member of the Washington House of Representatives representing District 15-Position 2 from 2003 through 2009 and as Washington Director of Agriculture from 2009 to 2013. Newhouse was first elected to the state House in 2002 and served until he was named state Director of Agriculture in 2009. He was first appointed by Governor Christine Gregoire on February 18, 2009.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.